Each month, GHEA aggregates the latest news and research related to place-based tobacco control and geographic health disparities. Below you will find the latest posts, updated regularly throughout the month.
(Last updated: April 15, 2022)
General Tobacco Control News and Research
- CDC’s Office on Smoking and Health recently announced new social media ads about the risks of youth e-cigarette use, including the association of nicotine and impacts on youth mental health. The new ads are available in the CDC’s Media Campaign Resource Center.
- A simulation study examining the potential public health impact of the recent menthol ban in cigarettes and cigars found that as a result of the ban, overall smoking was estimated to decline by 15% by 2026.
- A study describes the development and application of a schema to characterize the comprehensiveness of flavored tobacco product sales restrictions.
- The FDA recently announced that it will regulate tobacco products containing nicotine from any source including non-tobacco nicotine, such as synthetic nicotine.
- Researchers find that an evidence-based cardiovascular disease risk reduction intervention improved rates of tobacco screening and cessation support in small primary care practices in North Carolina.
- A CDC study examines data on the prevalence of use of tobacco products, alcohol, and other substances in U.S. high school students throughout the COVID-19 pandemic. One major finding from the study is that one in three high school students stated they used substances more during the pandemic compared to prior use.
- The CDC Foundation recently released a new national and state data brief through 2021 which provide updates on trends in unit sales of e-cigarettes in the United States by product and flavor type.
- A study examining prescription smoking cessation medication fills and spending from 2009-2019 found that total fills and spending decreased from 2009 to 2013 and then increased through 2019, whereas patient spending decreased. Possible reasons for these trends include the gradual implementation of federal requirements for insurance coverage of cessation medications and reduced cost sharing and financial barriers.
